MedTrace Logo

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

NCT00319189 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2006-05-10

No results posted yet for this study

Summary

The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.

Conditions

  • Renal Transplant Recipients
  • Posttransplant Diabetes Mellitus
  • Posttransplant Impaired Glucose Tolerance

Interventions

DRUG

Nateglinide

Sponsors & Collaborators

  • University of Oslo School of Pharmacy

    lead OTHER

Principal Investigators

  • Trond Jenssen, MD, PhD · Rikshospitalet, Section of Nephrology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Completion
2003-11-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319189 on ClinicalTrials.gov